
22 Mar 2016
Final results; strong prospects but 2016 set to be a quiet year
The main highlights for Synairgen in 2015 were the research collaboration with Pharmaxis and AstraZeneca commencing its Phase IIa trial of AZD9412 (formally SNG001). News flow from both is expected in 2017 with the former commencing clinical trials and the later announcing data. The group has also announced positive, albeit very early, data from its collaboration with Pharmaxis this morning. Synairgen continues to screen for new opportunities and expects to establish at least one in the coming y ....

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Final results; strong prospects but 2016 set to be a quiet year
Synairgen plc (SYGGF:OTC) | 0 0 0.0% | Mkt Cap: 287.0m
- Published:
22 Mar 2016 -
Author:
Singer CM Team -
Pages:
3 -
The main highlights for Synairgen in 2015 were the research collaboration with Pharmaxis and AstraZeneca commencing its Phase IIa trial of AZD9412 (formally SNG001). News flow from both is expected in 2017 with the former commencing clinical trials and the later announcing data. The group has also announced positive, albeit very early, data from its collaboration with Pharmaxis this morning. Synairgen continues to screen for new opportunities and expects to establish at least one in the coming y ....